Ublituximab: Difference between revisions
Content deleted Content added
No edit summary |
templated cite |
||
Line 46: | Line 46: | ||
'''Ublituximab''' is an [[Immunotherapy#Immunomodulators|immunomodulator]]. It binds to [[CD20]].<ref>{{cite journal | author = [[World Health Organization]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 104 | journal = WHO Drug Information | volume = 24 | issue = 4 | year = 2010 | url =https://www.who.int/medicines/publications/druginformation/innlists/Final_PL104.pdf }}</ref> |
'''Ublituximab''' is an [[Immunotherapy#Immunomodulators|immunomodulator]]. It binds to [[CD20]].<ref>{{cite journal | author = [[World Health Organization]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 104 | journal = WHO Drug Information | volume = 24 | issue = 4 | year = 2010 | url =https://www.who.int/medicines/publications/druginformation/innlists/Final_PL104.pdf }}</ref> |
||
It is in [[phases of clinical research|Phase 3 clinical trials]] for [[multiple sclerosis]].<ref> |
It is in [[phases of clinical research|Phase 3 clinical trials]] for [[multiple sclerosis]].<ref>{{ClinicalTrialsGov|NCT03277261|A Phase 3, Randomized, Multi-center, Double-blinded, Active-controlled Study to Assess the Efficacy and Safety/Tolerability of Ublituximab (TG-1101; UTX) as Compared to Teriflunomide in Subjects With Relapsing Multiple Sclerosis (RMS) (ULTIMATE 1)}}</ref> |
||
It is also in "U2" Phase 3 clinical trials for [[chronic lymphocytic leukemia]] in combination with Umbralisib. |
It is also in "U2" Phase 3 clinical trials for [[chronic lymphocytic leukemia]] in combination with Umbralisib. |
Revision as of 10:59, 23 January 2021
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Chimeric (mouse/human) |
Target | CD20 |
Clinical data | |
ATC code |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
KEGG | |
(what is this?) (verify) |
Ublituximab is an immunomodulator. It binds to CD20.[1]
It is in Phase 3 clinical trials for multiple sclerosis.[2]
It is also in "U2" Phase 3 clinical trials for chronic lymphocytic leukemia in combination with Umbralisib.
See also
References
- ^ World Health Organization (2010). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 104" (PDF). WHO Drug Information. 24 (4).
- ^ Clinical trial number NCT03277261 for "A Phase 3, Randomized, Multi-center, Double-blinded, Active-controlled Study to Assess the Efficacy and Safety/Tolerability of Ublituximab (TG-1101; UTX) as Compared to Teriflunomide in Subjects With Relapsing Multiple Sclerosis (RMS) (ULTIMATE 1)" at ClinicalTrials.gov